Charting the Decline of the Fourth Wave: US Overdose Deaths by Race, Ethnicity, and Substance Involvement

Joseph R. Friedman, MD, PhD, MPH[1*], Joseph J. Palamar, PhD[2], Daniel Ciccarone, MD[3], Tommi L. Gaines, DrPH[4], Annick Borquez, PhD[4], Chelsea L. Shover, PhD[5], Steffanie A. Strathdee, PhD[4]

[1]Department of Psychiatry, University of California, San Diego, San Diego, CA
[2]Department of Population Health, NYU Grossman School of Medicine, New York, NY
[3]Department of Family Community Medicine, University of California, San Francisco, San Francisco, CA
[4]Department of Medicine, University of California, San Diego, San Diego, San Diego, CA
[5]Department of Medicine, University of California Los Angeles, Los Angeles, CA

*Correspondence to:
Joseph Friedman, MD PhD, MPH, University of California, San Diego, 200 W Arbor Dr, San Diego, CA, 92103. Joseph.robert.friedman@gmail.com

Word Count: 1,996 words
Keywords: fentanyl, fourth wave overdose crisis, overdose surveillance, polysubstance use, stimulants, substance use disorders

Abstract

Aims: To characterize decreases in overdose death rates in the United States between 2023 and 2024 by race/ethnicity, and substance involvement.

Design: Population-based study of national death records accessed via the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data for Epidemiologic Research (WONDER) platform using an underlying cause of death approach.

Setting: United States (US).

Participants/cases: All individuals who died from drug overdose between January 1999 and December 2024.

Measurements: Annual overdose deaths per 100,000 population. Year of occurrence of overdose death; substance involvement; race/ethnicity of decedents.

Findings: After many years of increases, the US overdose death rate dropped 24.4% between 2023 and 2024. Decreases reflected declining illicit fentanyl-involved deaths (with and without stimulant involvement). The fourth wave of the US overdose crisis—defined by deaths involving fentanyl together with stimulants—declined for the first time in 2024. Despite overall decreases, deaths involving stimulants without fentanyl, and xylazine, continued to represent a growing fraction of overdose fatalities. Non-Hispanic Black and African Americans had the largest decrease in death rates in 2023-2024—falling 29.3%, but remained elevated at 36.0 per 100,000, 1.51 times higher than the national average of 23.7 per 100,000. Non-Hispanic American Indian and Alaska Native individuals had the highest overdose death rates rate in 2024, at 50.8 per 100,000, representing 2.15 times the national average rate, and experienced a below-average relative decrease of 20.1%.

43 **Conclusions**

44 All four previously defined waves of the US overdose crisis are in decline, as deaths involving
45 illicit fentanyl, with and without stimulants, are dropping sharply. Concurrently, the fraction of
46 overdose deaths involving stimulants without fentanyl and those involving xylazine, continued
47 to increase. While racial disparities in drug overdose death rates narrowed slightly during this
48 period, significant gaps remain, with the highest rates among American Indian, Alaska Native,
49 and Black individuals.

Introduction

After many years of rapid increases, overdose death rates in the US have begun decreasing, drawing considerable public attention (1–3).

The US overdose crisis has been characterized by a 'four-wave' paradigm, wherein an escalating death rate was attributed to shifting drug profiles over time (4–6). The first wave entailed a surge in deaths involving commonly prescribed opioids (7). Subsequently, in wave two, drug overdose deaths involving heroin increased rapidly (8). Wave three saw the market takeover of illicitly-manufactured synthetic opioids, primarily fentanyls (8). The fourth wave quickly followed, involving the polysubstance use of fentanyl with illicit stimulants such as cocaine and methamphetamine (4,5). Deaths involving the combination of fentanyl with the veterinary sedative xylazine also increased during this period (9,10). Polysubstance overdose deaths are not a new phenomenon—for instance, benzodiazepines were frequently co-involved in prescription opioid deaths during the first wave (11)—however the fourth wave has been characterized by a particularly lethal rise in intentional and unintentional polysubstance drug use (12).

These four waves of the overdose crisis have also seen epidemiological differences by race/ethnicity. Black and African Americans have been disproportionately affected by waves three and four of the crisis (13). American Indian and Alaska Native individuals have been disproportionately affected by all waves of the overdose crisis, with disparities worsening sharply in recent years (13). One study found that death rates decreased among Non-Hispanic White individuals as of 2023, but they were still increasing among the most affected

71 racial/ethnic minority groups, suggesting widening disparities despite overall gains at the
72 population level (3).

73 Here, we leverage recent records to describe updated overdose death rates between
74 January 1999-December 2024 by substance-involvement and race/ethnicity.

75 **Methods**

76 Comprehensive national death data, representing all registered overdose deaths in the US, were
77 obtained for the 1999-2024 period, stratified by year, month, race/ethnicity, and substance-
78 involvement via the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data
79 for Epidemiologic Research (WONDER) platform using an underlying causes of death (UCD)
80 approach (14). Overdose deaths were defined by ICD-10 UCD X40–X44 (unintentional), X60–X64
81 (suicide), X85 (homicide), and Y10–Y14 (undetermined intent) (14). Substance involvement was
82 secondarily characterized using ICD-10 multiple cause of death codes, including prescription
83 opioids (T40.2), heroin (T40.1), synthetic opioids (primarily and herein referred to as fentanyl)
84 (T40.4) (5), cocaine (T40.5), psychostimulants with abuse potential (primarily and herein
85 referred to as methamphetamine) (T43.6) (15), and xylazine (T42.7 or T46.5) (9).

86 We calculated fentanyl-deleted death rates for prescription opioids, heroin, cocaine,
87 methamphetamine, and stimulants (either cocaine or methamphetamine), to assess trends for
88 each substance, removing the influence of fentanyl co-involvement. For each, this entailed
89 subtracting the death rate from the substance together with fentanyl from the total death rate
90 for the substance.

Recorded deaths from 2024 were provisional and may slightly underestimate finalized records, whereas records from 2023 and prior were finalized. All death rates were crude per 100,000 population. All analyses were conducted in R version 4.4.1.

Results

Figure 1 provides a simplified schematic representing trends in the four waves of the US overdose crisis from 1999 through 2024. Death rates involving prescription opioids and heroin (with fentanyl co-involved deaths omitted) reached inflection points and began to fall in 2017 and 2016, respectively, marking the decline of waves one and two of the crisis. Overdose death rates involving illicit fentanyl without stimulant co-involvement began to fall in 2022, marking the decline of wave three. Overdose death rates involving fentanyl with stimulants declined for the first time in 2024, beginning the decline of wave four. Deaths involving methamphetamine (without fentanyl co-involvement) and cocaine (without fentanyl co-involvement) continued increasing between 2023 and 2024, consistent with an overall trend of increasing stimulant-related deaths. Deaths involving xylazine also held steady and represented an increasing proportion of fentanyl-involved deaths between 2023 and 2024, rising from being co-involved in 8.3% of fentanyl-involved overdose deaths in 2023 to 12.6% of fentanyl-involved deaths in 2024.

The overall decrease in overdose deaths in the US in 2023-2024 has been largely driven by declines in deaths involving illicit fentanyl (Figure 2). Fentanyl-involved deaths without and with stimulants dropped from 31,193 and 41,583 in 2023, respectively, to 19,673 and 28,062 in 2024. In contrast, the number of deaths involving stimulants, without fentanyl, grew from 18,142 in 2023 to 18,907 in 2024, representing 17.3% of all overdose deaths in 2023, and 23.8% of overdose deaths in 2024 (Figure 2).

Although all groups saw progress, decreases in overdose death rates also varied by race/ethnicity (Figure 3). Averaging across all racial groups, overdose death rates fell to 23.7 per 100,000 in 2024, representing a 24.4% reduction from 2023. Non-Hispanic Black and African Americans had the largest decrease in overdose death rates between 2023 and 2024 of any group assessed, falling by 14.94 per 100,000 to reach 35.99 per 100,000 (a 29.3% reduction). This death rate nevertheless represented 1.51 times the national average in 2024. Non-Hispanic American Indian and Alaska Native individuals had the highest overdose death rates of any group assessed in 2024, at 50.8 per 100,000 (representing 2.15 times the national average), and experienced an above-average absolute decrease in death rate from 2023 of 12.78 per 100,000, although this represented a below-average relative decrease of 20.1%.

Non-Hispanic White individuals had approximately average overdose death rates in 2024 of 24.8 per 100,000 (1.04 times the national average) and saw a year-over-year percent decrease (23.9%) similar to the national average.

Death rates involving fentanyl with and without stimulants continued to disproportionately affect Non-Hispanic Black and Non-Hispanic American Indian and Alaska Native individuals (Figure 3). Cocaine-involved overdose deaths (with fentanyl deleted) disproportionately affected Non-Hispanic Black and African Americans for all years assessed, with this disparity rising to 3.13 times the national average by 2024. Methamphetamine-involved deaths (with fentanyl deleted) disproportionately affected Non-Hispanic American Indian and Alaska Native individuals, with an overdose rate 3.24 times above the national average in 2024. Xylazine-involved overdose deaths disproportionately affected Black and African Americans, with a rate of 1.66 times the national average in 2024.

135 **Discussion**

136 After many years of increasing overdose death rates, the US is in the midst of a historic moment
137 in the trajectory of the overdose crisis, with sharply decreasing trends observed between 2023-
138 2024. Although the beginning of these downward trends was previously reported (3), here we
139 provide newfound details documenting their continued trajectory, significance, and profundity.
140 We show that in 2024, for the first time, wave four of the crisis (defined by fentanyl in
141 combination with stimulants), is also decreasing in magnitude. This simultaneous, large-scale
142 reduction in deaths involving fentanyl—both as a standalone driver and in polysubstance
143 combinations—is a remarkable epidemiological shift, accounting for the vast majority of the
144 overall national decline in drug overdose deaths.

145 Nevertheless, we also highlight that not all segments of the US overdose crisis are
146 shrinking. The persistent increase in drug overdose deaths involving stimulants without
147 fentanyl—even as overall and fentanyl-involved deaths rapidly decline—represents a striking
148 divergence. If these diverging trends continue, stimulants may soon surpass opioids to become
149 the defining addiction-related public health challenge in the US. Other stimulant-related health
150 harms, such as substance-induced psychosis, have also risen (16). It is also important to note
151 that the majority of stimulant-related burden of disease stems from slower epidemiological
152 processes compared to overdose, such as accelerated cardiovascular, neurovascular, pulmonary,
153 and psychiatric consequences (17). As stimulants continue to drive a growing share of addiction-
154 related burden of disease, a focus on overdose deaths as the defining indicator of the public
155 health impact of substance use disorders may be increasingly insufficient. Instead, more

156 comprehensive measures such as disability adjusted life years (DALYS) (17) that account for
157 morbidity may more completely reflect the trajectory of the US addiction crisis.

158 After several years of rapidly widening inequalities in race/ethnicity—driven by a
159 profound divergence that occurred during the COVID-19 pandemic—2024 showed encouraging
160 decreases in drug overdose death rates across all groups. Most notably, Black and African
161 Americans experienced the largest absolute drop, with rates falling by nearly one-third in a
162 single year, which also contributed to a modest narrowing of racial disparities. Nevertheless,
163 because of the sheer magnitude of prior disparities, inequalities remain large through 2024. In
164 particular, the death rate among American Indian and Alaska Natives remains over double that
165 of the general population. Importantly, the substances with increasing importance through
166 2024—cocaine, methamphetamine, and xylazine—all show marked racial inequalities,
167 suggesting that disparities may not decrease in future years without intervention. Policies
168 targeting community and system-level factors associated with inequitable health will be needed
169 to address these persistent gaps (13,18,19).

170 The decreases in overdose deaths in 2023-2024 in the US are likely multifactorial in
171 nature, reflecting several overlapping epidemiological and demographic phenomena (3,20–23).
172 Simulation models have suggested that decreases in the at-risk population may be single most
173 important driver (23), reflecting increased awareness of the risks of illicit fentanyl among the
174 population, as well as extensive premature mortality not replaced by new individuals
175 commencing fentanyl use (3,20,23).

176 Alternatively other research has suggested that sudden decreases in the availability
177 and/or purity of illicit fentanyl—a “fentanyl drought”—may be a key driving factor, and may

178 better explain the abruptness of the drop in deaths (20,22,24). One analysis used fentanyl
179 purity data from law enforcement seizures, as well as content analysis from social media, to
180 argue that a supply shock occurred in the US and Canada that was temporally aligned with
181 decreases in overdose deaths, and which may have been related to disruptions in availability of
182 fentanyl precursors from China (22).

183 Several other factors are likely also playing a role. Overdose deaths spiked during COVID-
184 19, and they are now receding alongside several other social, economic, and epidemiological
185 consequences of the pandemic (25). The availability and use of the opioid receptor antagonist
186 naloxone, which is a short-term reversal agent for opioid overdoses, have also been
187 considerably scaled up in recent years (26,27). The widespread shift from injecting to smoking
188 opioids has been associated with decreased overdose risk (28,29). Further research is needed
189 to assess the relative contributions of these factors.

190 Some of these observed trends may also simply reflect, at least in part, an overall
191 'regression to the mean' as trends homogenize in the context of nearly universal decreases.
192 Examining demographic categories highlights that the groups with the highest drug overdose
193 death rates—such as Black and African American, and American Indian and Alaska Native
194 populations—generally experienced the greatest absolute decreases, which would align with
195 this statistical phenomenon.

196 **Limitations**

197 Death records from 2024 are provisional and may change when final records are released (30).
198 The race/ethnicity categorizations used here have limitations, especially for American Indian
199 and Alaska Native individuals, which may mask the magnitude of inequalities (31). Furthermore,

200 changes in race classification standards within national death data between 2017 and 2018
201 introduce a potential break in data continuity (32). Multiracial individuals were excluded from
202 both death and population counts starting in 2018 in our analysis, which represents a limitation
203 that may subtly affect longitudinal estimates. Nevertheless, trends analyzed between 2018 and
204 2024 are internally consistent.

205 **Conclusions**

206 Recent decreases in overdose deaths are encouraging and relatively unprecedented. Despite
207 recent progress, US overdose death rates remain a global outlier (33). The country saw about
208 80,000 deaths in 2024. If the US population had the same overdose death rate as Western
209 Europe, about 9,000 lives would have been lost (17). Greater investments are needed to
210 sustainably reverse the course of this large-magnitude, preventable death crisis, via evidence-
211 based approaches such as medications for opioid use disorder, harm reduction, and access to
212 addiction-related treatment.

213 Some encouraging, yet early, improvements in racial/ethnic inequalities in overdose
214 death rates have also been seen, after profoundly worsening during the COVID-19 pandemic
215 (13). Yet disparities remain, even as the national trend in deaths now declines. More progress
216 can be made with tailored solutions to reduce overdose deaths among the most affected groups
217 (13).

218 The fraction of drug overdose deaths involving stimulants without fentanyl and those
219 involving xylazine continue to increase, highlighting shifting challenges in the overdose crisis.

220

221

Funding

JRF and SAS received funding from the National Institute on Drug Abuse (1U01DA063078-01). DC was supported by National Institute on Drug Abuse (R01DA054190). CLS was supported by National Institute on Drug Abuse (R01DA057630; K01DA05771**).** AB was supported by National Institute on Drug Abuse (R33DA061260 and DP2DA049295). Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Conflicts of Interest

JP reported receiving personal fees from the Washington-Baltimore High Intensity Drug Trafficking Areas program, Elsevier, Wiley, Rutgers University, Arizona State University, the University of Southern California, the Substance Abuse and Mental Health Services Administration, Queensland University, the National Network of Public Health Institutes, Alta Mira Recovery programs, and Dartmouth University, and nonfinancial support from NIH/NIDA, the University of Florida, Rx Summit, the American College of Neuropsychopharmacology, and the Reagan-Udall Foundation for the FDA during the conduct of the study. DC reports personal fees from Emergent Biosciences outside the submitted work. All other authors declare no conflict of interest.



Figure 1. Simplified Representation of the Four Waves of the US Overdose Crisis
Based on the general approach from Friedman and Shover, the four waves of the US overdose crisis are shown in a simplified schema. Wave one is represented by prescription opioids (with fentanyl co-involvement deleted), wave 2 is shown by deaths involving heroin (without fentanyl). Wave 3 and 4 correspond to fentanyl-involved deaths without, and with, stimulants, respectively. Xylazine and stimulants without fentanyl are shown as examples of more recent drug trends that are not decreasing. Note that most xylazine-involved deaths also involve fentanyl. Data from 2024 are provisional and may slightly underestimate final numbers.



Figure 2. Overdose Deaths by Stimulant and Fentanyl Involvement
The total number of annual overdose deaths each year is shown by categories of fentanyl and stimulant involvement. Data from 2024 are provisional and may slightly underestimate final numbers.



Figure 3. Overdose Deaths by Substance and Race/Ethnicity, 1999-2024
Overdose deaths per 100,000 population are shown separately by substance involvement and race/ethnicity between 1999 and 2024. Rx opioids without fentanyl, heroin without fentanyl, fentanyl without stimulants, and fentanyl with stimulants correspond roughly to waves 1,2,3 and 4, of the overdose crisis, respectively. Deaths involving xylazine, and stimulants without fentanyl, represent trends continuing to rise in 2024, despite overall decreases in death totals. Data from 2024 are provisional. Changes in race classification standards within national mortality data around between 2017 and 2018 introduce a potential break in data continuity, although we do not note particularly large discontinuities. Prior to 2018, individuals were all assigned to a single race. Starting in 2018, multiple race was an available category, and these individuals were excluded from the current analysis.

References

1. U.S. Overdose Deaths Decrease in 2023, First Time Since 2018 [Internet]. Centers for Disease Control and Prevention; 2024. Available from: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm

2. Ahmad F, Cisewski J, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2025. [Internet]. 2020 Dec. Available from: https://dx.doi.org/10.15620/cdc/20250305008

3. Post LA, Ciccarone D, Unick GJ, D'Onofrio G, Kwon S, Lundberg AL, et al. Decline in US Drug Overdose Deaths by Region, Substance, and Demographics. JAMA Netw Open. 2025 Jun 12;8(6):e2514997. doi:10.1001/jamanetworkopen.2025.14997

4. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Current Opinion in Psychiatry. 2021 Jul;34(4):344–50. doi:10.1097/YCO.0000000000000717

5. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. Addiction. 2023;118(12):2477–85. doi:10.1111/add.16318

6. Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018 Sep 21;361(6408):eaau1184. doi:10.1126/science.aau1184 PubMed PMID: 30237320.

7. Friedman J, Kim D, Schneberk T, Bourgois P, Shin M, Celious A, et al. Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California. JAMA Internal Medicine. 2019 Apr 1;179(4):469–76. doi:10.1001/jamainternmed.2018.6721

8. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019 Sep;71:183–8. doi:10.1016/j.drugpo.2019.01.010 PubMed PMID: 30718120; PubMed Central PMCID: PMC6675668.

9. Friedman JR. Assessing an ICD-10 Code Approach for Estimating Xylazine-Involved Overdose Deaths in the United States. Drug and Alcohol Dependence. 2025 Jul;112781. doi:10.1016/j.drugalcdep.2025.112781

10. Gupta Rahul, Holtgrave David R., Ashburn Michael A. Xylazine — Medical and Public Health Imperatives. New England Journal of Medicine. 2023 Jun 14;388(24):2209–12. doi:10.1056/NEJMp2303120

11. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017 Mar 14;356:j760. doi:10.1136/bmj.j760

12. Friedman J, Ciccarone D. The public health risks of counterfeit pills. The Lancet Public Health. 2025 Jan;10(1):e58–62. doi:10.1016/S2468-2667(24)00273-1

13. Friedman JR, Nguemeni Tiako MJ, Hansen H. Understanding and Addressing Widening Racial Inequalities in Drug Overdose. AJP. 2024 May 1;181(5):381–90. doi:10.1176/appi.ajp.20230917

14. CDC WONDER [Internet]. Available from: https://wonder.cdc.gov/

15. Han B, Cotto J, Etz K, Einstein EB, Compton WM, Volkow ND. Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity. JAMA Psychiatry. 2021 Jan 20. doi:10.1001/jamapsychiatry.2020.4321

16. Calcaterra SL, Yamkovoy K, Swathi PA, Ciccarone D, Del Pozo B, Englander H, et al. U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015-2019. Drug Alcohol Depend. 2024 Sep 1;262:111409. doi:10.1016/j.drugalcdep.2024.111409 PubMed PMID: 39089187; PubMed Central PMCID: PMC11343609.

17. Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024 May 18;403(10440):2100–32. doi:10.1016/S0140-6736(24)00367-2 PubMed PMID: 38582094.

18. Gondré-Lewis MC, Abijo T, Gondré-Lewis TA. The Opioid Epidemic: a Crisis Disproportionately Impacting Black Americans and Urban Communities. J Racial and Ethnic Health Disparities. 2023 Aug;10(4):2039–53. doi:10.1007/s40615-022-01384-6

19. Bauer C, Hassan GH, Bayly R, Cordes J, Bernson D, Woods C, et al. Trends in Fatal Opioid-Related Overdose in American Indian and Alaska Native Communities, 1999–2021. American Journal of Preventive Medicine. 2024 Jun;66(6):927–35. doi:10.1016/j.amepre.2024.01.019

20. Dowell D, Nataraj N, Rikard M, Park J, Zhang K, Baldwin G. Why have overdose deaths decreased? Widespread fentanyl saturation and decreased drug use among key drivers. The Lancet Regional Health – Americas. doi:10.1016/j.lana.2025.101226

21. CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths [Internet]. 2025. Available from: https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html

22. Vangelov K, Humphreys K, Caulkins JP, Pollack H, Pardo B, Reuter P. Did the illicit fentanyl trade experience a supply shock? Science. 2026 Jan 8;391(6781):134–6. doi:10.1126/science.aea6130

23. Stringfellow EJ, Lim TY, Hasgul Z, Jalali MS. Structural Drivers of the Drop in Opioid Overdose Deaths in the US. JAMA Psychiatry. 2025 Nov 26. doi:10.1001/jamapsychiatry.2025.3584

24. Shover CL, Koncsol AJ, Godvin ME, Goodman-Meza D, Pardo B, Poimboeuf M, et al. High variation in purity of consumer-level illicit fentanyl samples in Los Angeles, September 2023–April 2025. International Journal of Drug Policy. 2025 Nov 1;145:104977. doi:10.1016/j.drugpo.2025.104977

25. Friedman J, Akre S. COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States, January–July 2020. Am J Public Health. 2021 Apr 15;e1–8. doi:10.2105/AJPH.2021.306256

26. Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. The Lancet Public Health. 2022 Mar 1;7(3):e210–8. doi:10.1016/S2468-2667(21)00304-2

27. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013 Jan 31;346:f174. doi:10.1136/bmj.f174

28. Eger WH, Abramovitz D, Bazzi AR, Bórquez A, Vera CF, Harvey-Vera A, et al. Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020–2023. Drug and Alcohol Dependence. 2024 Jun 1;259:111318. doi:10.1016/j.drugalcdep.2024.111318

29. Karandinos G, Unick J, Ciccarone D. Mortality risk among individuals who smoke opioids compared with those who inject: A propensity score-matched cohort analysis of United States national treatment data. Addiction. 2025 May 1;120(5):1040–5. doi:10.1111/add.16740

30. Spencer MR. Timeliness of Death Certificate Data for Mortality Surveillance and Provisional Estimates. CDC Vital Statistics Rapid Release. 2016;8.

31. Anderson RN, Copeland G, Hayes JM. Linkages to Improve Mortality Data for American Indians and Alaska Natives: A New Model for Death Reporting? Am J Public Health. 2014 Jun;104(S3):S258–62. doi:10.2105/AJPH.2013.301647

32. Heron M. Comparability of Race-specific Mortality Data Based on 1977 Versus 1997 Reporting Standards.

33. Gumas E. U.S. Overdose Deaths Remain Higher Than in Other Countries — Trend-Tracking and Harm-Reduction Policies Could Help [Internet]. Commonwealth Fund; 2025. Available from: https://www.commonwealthfund.org/blog/2025/us-overdose-deaths-remain-higher-other-countries-trend-tracking-and-harm-reduction?check_logged_in=1